Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  leuprolide acetate
Find trials that include:  Any drugs shown
Results 1-18 of 18 for your search:
Start Over
Antiandrogen Therapy and Radiation Therapy with or without Docetaxel in Treating Patients with Prostate Cancer That Has Been Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NRG-GU002, NCI-2016-00963, NCT03070886
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-13, NCI-2015-00824, NCT02319837
Stereotactic Body Radiation Therapy and Hormone Therapy in Treating Patients with Localized Intermediate-Risk Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11157, NCI-2013-01332, CIR00008893, NA_00067963, NA_00067963/CIR00003978, NCT01517451
High-Dose Brachytherapy in Treating Patients with Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: PROS0065, NCI-2015-00089, 350, NCT02346253
Abiraterone Acetate, Radiation Therapy, and Hormone Therapy in Treating Patients with Unfavorable-Risk Localized Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 20 to 80
Trial IDs: Pro00044071, NCI-2013-01803, NCT01717053
Palifermin with Leuprolide Acetate after Total-Body Irradiation Based Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 to 60
Trial IDs: 12-077, NCI-2012-02983, NCT01746849
Enzalutamide and Leuprolide Acetate before, during, and after Radiation Therapy in Treating Patients with High-Risk Localized or Locally Advanced Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SCCC-16813, NCI-2014-02533, 082013-032, 8843, NCI-2014-02510, NCT02064582
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients with Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 135513, NCI-2015-01058, 14-13335, NCI-2015-00154, NCT02168062
Enzalutamide versus Standard Androgen Deprivation Therapy in Reducing Incidence of Metabolic Syndrome in Patients with Advanced Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 19 and over
Trial IDs: 14-0909, NCI-2014-02219, NCT02278185
Enzalutamide and Leuprolide Acetate after Radiation Therapy in Treating Patients with High-Risk Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15558, NCI-2015-01757, 147883, CC #15558, NCI-2015-01748, NCT02508636
Hormone Therapy and Docetaxel before Surgery and Radiation Therapy in Treating Patients with Newly Diagnosed Oligometastatic Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1618, NCI-2016-00836, CRMS-63459, IRB00070003, NCT02716974
Androgen Receptor Antagonist ARN509 and Leuprolide Acetate in Treating Patients with Prostate Cancer before Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CASE5815, NCI-2016-01612, NCT02770391
Abiraterone Acetate and Apalutamide before and after Surgery in Treating Patients with Intermediate-High Risk Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-223, NCI-2016-01764, NCT02903368
Androgen Deprivation Therapy, Pembrolizumab, and High Dose Rate Brachytherapy with or without TLR9 Agonist SD-101 in Treating Patients with Metastatic Prostate Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16703, NCI-2017-01340, 16-18989, NCT03007732
Pexidartinib, Radiation Therapy, and Antihormone Therapy in Treating Patients with Intermediate- or High-Risk Prostate Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-075, NCI-2015-00742, 1501013723, NCT02472275
Intensity Modulated Radiation Therapy with Stereotactic Radiosurgery Boost and Hormone Therapy in Treating Patients with Prostate Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: CCRO025, NCI-2014-01486, 421870, NCT02064036
Start Over